Life sciences firm Exelixis plans Alameda expansion
The biotech company agrees to lease yet-to-be-built offices
ALAMEDA >> Exelixis, a fastexpanding life sciences firm with nearly $1 billion in revenue, has struck a deal to lease a big office building for the company’s new headquarters, developers said.
The biotech company has leased a yet-to-be-built office building in Alameda that, when constructed and complete, will total 220,000 square feet, according to project developers srmErnst
Development Partners and Hillwood Properties.
The building will rise at 1951 Harbor Bay Parkway and appears to be a sleek and modern campus, according to conceptual images provided by the developers.
“Harbor Bay Business Park is quickly expanding as businesses migrate from San Francisco and the Peninsula for better growth opportunities,” said Joe Ernst, president of srmErnst.
The rental transaction represents a major expansion for Exelixis.
Alameda-based Exelixis already occupies three buildings on Harbor Bay Parkway that together total 135,000 square feet, including the current corporate headquarters at 1851 Harbor Bay Parkway that total 64,000 square feet.
Plus, Exelixis is preparing moves into two other buildings besides the big one that it has just leased. The other smaller office buildings are at 1601 Harbor Bay Parkway, totaling 37,000 square feet, and 1701 Harbor Bay Parkway, totaling 59,000 square feet.
At present, Exelixis has a headcount in Alameda of
roughly 600 workers, the company said Friday.
The large unbuilt modern office building of 220,000 square feet at 1951 Harbor Bay Parkway is expected to accommodate 900 employees. All
told, when the new headquarters is complete, Exelixis anticipates it will occupy 440,000 square feet in Alameda. That includes offices and lab spaces.
Over the 12 months that ended in September, Exelixis earned $612.4 million on revenue of $956.1 million. For the calendar year of 2018, Exelixis
earned $690.1 million on revenue of $853.8 million.
“The underlying driver of all of this expansion work is the company’s continued growth,” Exelixis stated in the emailed comments.
Exelixis specializes in the creation and commercialization of medicines to combat cancers that are difficult to treat.
The development of the new Exelixis headquarters is scheduled to begin this summer. The developers didn’t provide a precise timeline for completion, however.
“We’re excited to see the expansion of companies like Exelixis continue the evolution of this area into a great place to do important work,” Ernst said.